{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~43 mi. (Ponderano, Italy, +383 more cities)
facility
Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
city
~64 mi. (Turin, Italy, +44 more cities)
facility
AOU City of Health and Science of Turin
biomarker
BCL2 Fusion, +2 more biomarkers
condition
Diffuse Large B-Cell Lymphoma, +3 more conditions
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +3 more types
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~68 mi. (Orbassano, Italy, +93 more cities)
facility
AOU San Luigi Gonzaga di Orbassano ( Site 0595)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~68 mi. (Orbassano, Italy, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~68 mi. (Orbassano, Italy, +142 more cities)
facility
AOU San Luigi Gonzaga
biomarker
del(11)(q10), +27 more biomarkers
drug
imetelstat, +1 more drug